Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 4/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039533 | 0.88 | PARP1 (0.60) | PARP1ALDH1A1PARP2 | |
| SCHEMBL7111338 | 0.88 | PARP1 (0.80) | PARP1ALDH1A1PARP2DHODH | |
| SCHEMBL31353202 | 0.88 | PARP1 (0.59) | PARP1ALDH1A1PARP2SMN1; SMN2BCHE | |
| SCHEMBL1033372 | 0.83 | PARP1 (0.62) | PARP1ALDH1A1PARP2KDM4ELMNA | |
| SCHEMBL1034851 | 0.80 | DHODH (0.55) | PARP1PARP2KDM4ESMN1; SMN2DHODH | |
| SCHEMBL1032829 | 0.79 | CHRNB2 (0.61) | PARP1ALDH1A1PARP2KDM4ESMN1; SMN2 | |
| SCHEMBL24186148 | 0.79 | ALDH1A1 (0.59) | PARP1ALDH1A1PARP2KDM4ELMNA | |
| SCHEMBL31353532 | 0.78 | AKT1 (0.45) | PARP1PARP2KDM4ELMNALDHA | |
| SCHEMBL9409728 | 0.78 | PARP1 (0.48) | PARP1ALDH1A1PARP2KDM4ESMN1; SMN2 | |
| SCHEMBL2629409 | 0.78 | ALDH1A1 (0.57) | PARP1ALDH1A1PARP2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-1998045272-A1 | TOPOISOMERASE INHIBITORS | LATROBE UNIVERSITY (AU) | 1998-10-15 | — | — | WO | disclosed |
| US-5721248-A | CALCIUM AGONISTS; TREATING CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-24 | — | — | US | disclosed |
| US-5545646-A | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | PARP1 183/4885ALDH1A1 2326/4885PARP2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.